• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Algorithme selects VCT to stop duplicate enrollment in clinical trials

Algorithme selects VCT to stop duplicate enrollment in clinical trials

December 7, 2015
CenterWatch Staff

Algorithme Pharma USA, an Altasciences company, has selected Verified Clinical Trials (VCT), the global clinical trial research subject database registry, to counter attempts at duplicate enrollment in clinical trial research.

The majority of phase I units in North America utilize Verified Clinical Trials, making it the largest North American clinical research subject database registry in both early and late phase clinical trials. Algorithme Pharma USA joins a vast network of research sites and pharmaceutical companies on a national and global level to prevent duplicate enrollment in clinical trials.

Simultaneously enrolling in multiple clinical trials, also known as duplicate enrollment in clinical trials, has become a serious problem in the clinical research world, as research volunteers attempt to jump from one study to another without waiting for the appropriate amount of time to lapse between studies. That process is typically done in an effort to earn more money or receive free care. By doing so, others are placed at risk, including the drug manufacturer, the research site and, most importantly, the volunteer. Furthermore, it may result in issues with the data quality.

Algorithme Pharma USA has taken a major step by choosing the VCT system to stop professional research subjects from duplicate enrollment in clinical trials. Algorithme Pharma USA is committed to volunteer safety and data quality; hence implementing the research subject database registry system to increase safety measures by preventing numerous protocol deviations.

Dr. Mitchell Efros, CEO of VCT, said, “Algorithme Pharma USA is the first clinical research unit in North Dakota to utilize a research subject database registry to prevent duplicate enrollment in clinical trials. By joining forces with Verified Clinical Trials, Algorithme Pharma USA has made a serious commitment to preventing duplicate enrollment in clinical trials as well as other protocol deviations while promoting subject safety and improving data quality.”

Algorithme Pharma USA President and CEO James Carlson said, “Having been in the clinical trial research business for over three decades, I am well aware of the issue of duplicate enrollment. Although we have exerted every effort to prevent it, never before have we had such a far reaching tool as offered by Verified Clinical Trials. We look forward to a close working relationship with Verified Clinical Trials.”

Upcoming Events

  • 17May

    Three Data Trends to Consider Now When Developing Your Decentralized Clinical Trial Strategy

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing